Lazard Asset Management
CSTL icon

Lazard Asset Management’s Castle Biosciences CSTL Stock Holding History

Lazard Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72
Closed -$1K – 1919
2025
Q2 		$1K Sell
72
-4,856
-99% -$89.9K ﹤0.01% 2249
2025
Q1 		$98K Buy
+4,928
New +$122K ﹤0.01% 1815
2023
Q1 		– Sell
-2,183
Closed -$51K – 2338
2022
Q4 		$51K Sell
2,183
-1,910
-47% -$44.3K ﹤0.01% 1798
2022
Q3 		$106K Buy
4,093
+821
+25% +$23K ﹤0.01% 1448
2022
Q2 		$71K Buy
3,272
+1,995
+156% +$46.4K ﹤0.01% 1652
2022
Q1 		$57K Buy
+1,277
New +$52.8K ﹤0.01% 1676

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's CSTL Position: Q3 2025 in Review

Lazard Asset Management sold out of Castle Biosciences (CSTL) in Q3 2025, closing a stake of 72 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in CSTL in Q1 2022 and held it in 6 quarters. The position peaked at $106K in Q3 2022. 173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Lazard Asset Management reported no remaining Castle Biosciences position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 72 Castle Biosciences shares in Q3 2025, an estimated $1K.
  • Lazard Asset Management first reported a position in Castle Biosciences in Q1 2022 and held it in 6 quarters.
  • Lazard Asset Management's Castle Biosciences position peaked at $106K in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.